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Introduction: Platelet-rich plasma (PRP) is nowadays widely applied in different clinical scenarios, such as
orthopedics, ophthalmology and healing therapies, as a growth factor pool for improving tissue regeneration.
Studies into its clinical efficiency are not conclusive and one of the main reasons for this is that different PRP
preparations are used, eliciting different responses that cannot be compared. Platelet quantification and the growth
factor content definition must be defined in order to understand molecular mechanisms behind PRP regenerative
strength. Standardization of PRP preparations is thus urgently needed.
Methods: PRP was prepared by centrifugation varying the relative centrifugal force, temperature, and time. Having
quantified platelet recovery and yield, the two-step procedure that rendered the highest output was chosen and
further analyzed. Cytokine content was determined in different fractions obtained throughout the whole
centrifugation procedure.
Results: Our method showed reproducibility when applied to different blood donors. We recovered 46.9 to 69.5%
of total initial platelets and the procedure resulted in a 5.4-fold to 7.3-fold increase in platelet concentration
(1.4 × 106 to 1.9 × 106 platelets/μl). Platelets were highly purified, because only <0.3% from the initial red blood
cells and leukocytes was present in the final PRP preparation. We also quantified growth factors, cytokines and
chemokines secreted by the concentrated platelets after activation with calcium and calcium/thrombin. High
concentrations of platelet-derived growth factor, endothelial growth factor and transforming growth factor (TGF)
were secreted, together with the anti-inflammatory and proinflammatory cytokines interleukin (IL)-4, IL-8, IL-13,
IL-17, tumor necrosis factor (TNF)-α and interferon (IFN)-α. No cytokines were secreted before platelet activation.
TGF-β3 and IFNγ were not detected in any studied fraction. Clots obtained after platelet coagulation retained a
high concentration of several growth factors, including platelet-derived growth factor and TGF.
Conclusions: Our study resulted in a consistent PRP preparation method that yielded a cytokine and growth factor
pool from different donors with high reproducibility. These findings support the use of PRP in therapies aiming for
tissue regeneration, and its content characterization will allow us to understand and improve the clinical outcomes.
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The major functions of platelets are preventing acute
blood loss and repairing vascular walls and adjacent
tissues after injury. During wound healing, platelets are
activated by contact with collagen, exposed to the blood-
stream after endothelial injury. Platelets secrete stored
intercellular mediators and cytokines from the cytoplas-
mic pool and release their α-granule content after ag-
gregation. This secretion is intense in the first hour
and platelets continue synthesizing more cytokines and
growth factors from their mRNA reserves for at least an-
other 7 days [1]. More than 800 different proteins are
secreted into the surrounding media [1,2], having a para-
crine effect on different cell types: myocytes [3], tendon
cells [3-7], mesenchymal stem cells from different ori-
gins [8-11], chondrocytes [12-14], osteoblasts [3,15,16],
fibroblasts [17-19] and endothelial cells [20]. Cell prolif-
eration, angiogenesis and cell migration are stimulated,
resulting in tissue regeneration. There are also reports
confirming that platelets secrete antimicrobial peptides,
suggesting an antibiotic effect [21].
Other properties were already proven for platelets re-
lated to their anti-inflammatory and analgesic effects
[22-24]. A clinical trial showed that platelet concentrates
had an analgesic effect [25] and Asfaha and colleagues
showed PAR4-mediated analgesic effects in vitro [26]. El-
Sharkawy and colleagues studied platelet secretions and
their effect on macrophage cultures, concluding that
platelet concentrates function as an anti-inflammatory
agent, because of the high RANTES and LXA4 concen-
trations [27].
Platelet-derived products include platelet-rich plasma
(PRP), which can be used with or without previous
platelet activation. Such preparations have been used
since the 1970s and they have been increasingly popular
since the 1990s [28]. Since then, different ways of pre-
paring PRP have emerged: from conventional blood cen-
trifugation to commercial systems; activated by adding
collagen, calcium and/or thrombin, by glass contact or
by freezing cycles; applied as platelet suspension or as a
gel; and the methodology continues to broaden [29-31].
The application of PRP in different tissues has given
promising results in different pathologies such as acute
and chronic injuries of bone and cartilage. Kon and col-
leagues reported observation of 91 patients (115 knees)
treated with PRP, which showed that PRP treatment is
safe, reduces pain and improves knee function, especially
in younger patients at 12 months [32]. This was superior
to hyaluronic acid viscosupplementation [32]. Subse-
quent analysis at 24 months, however, showed a pro-
gressive loss of the improvement and opened up the
question of possible repeated therapies [33]. This ex-
ample indicates the necessity for further studies even in
series with an extensive number of patients and providedwith controls. General opinion in recent reviews is that
the majority of reported clinical studies do not have suf-
ficient statistical power to give conclusive results. In
view of multiple potential PRP applications in orthope-
dics, sports medicine and reparative surgery, compara-
tive analyses of different clinical scenarios would be
useful. These comparisons are not feasible, mainly be-
cause PRP is a biological product, prepared using differ-
ent protocols, sometimes without even controlling
whether platelets were effectively concentrated and puri-
fied or whether an early activation occurred, discarding
all of the secreted growth factors within the platelet-
poor plasma (PPP). Another issue that is not even men-
tioned in clinical reports is whether there is a correlation
between the platelet concentration or the PRP volume
applied per injured area or volume. Studies have already
demonstrated that low platelet concentration is ineffi-
cient and that high concentrations have an inhibitory ef-
fect on cell growth, but results are still contradictory
[34-36]. Although still not deeply characterized, the leu-
kocyte content was also shown to be an important
factor, increasing inflammation and reducing tissue re-
generation in tendinopathies [37]. Preparation proce-
dures are also relevant, as shown by studies of the
chondro-inductive and osteo-inductive potential of PRP,
which is reported to be lost by thrombin activation [38]
and retained after freeze–thaw activation [39]. Consist-
ent nomenclatures, standardized protocols to produce
PRP as well as a full characterization of the final product
are still missing and would highly improve the compa-
rability of studies [40,41].
Combinations of PRP and mesenchymal stem cells
have been widely studied in vitro [8-11]. All of the au-
thors concluded that PRP increased cell proliferation but
divergences were found regarding the stem cell diffe-
rentiation capacity, some concluding that PRP favored
the osteogenic differentiation [9] and others demonstrat-
ing a chondrogenic compromise [10,12]. These variations
could be due to different PRP preparations, including or
not the leukocyte fraction, which can modify its growth
factor content. In both cases, PRP seemed to be a promis-
ing additive for stem cell transplantation for orthopedic
applications, by increasing the number of transplanted
stem cells and guiding their differentiation to a defined
cell type.
The present study was proposed to establish an opti-
mized and reproducible method for PRP preparation,
and to characterize the content in growth factors and
cytokines of the obtained fractions before and after
platelet activation. Our final goal is to develop and
characterize a PRP preparation for therapeutic pur-
poses, focusing on high platelet yield, purity and reco-
very without growth factor secretion throughout sample
manipulation.
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Ethics statement
All of the experimental procedures were approved by
the Ethics Research Committee of the Pro-Cardiaco
Hospital, Rio de Janeiro (CAAE: 04691712.3.0000.5533)
and all donors signed an informed consent.
Blood collection and platelet-rich plasma preparation
Peripheral blood from 22 healthy male and female vol-
unteer donors (20 to 54 years old) was collected using
blood collection tubes containing 0.5 ml citrate solution
(VacutainerW, Ref: 369714; BD Biosciences.
The PRP preparation procedure consisted of two cen-
trifugation steps. All steps were performed in a refriger-
ated centrifuge (certified Jouan Br4i, Saint-Herblain,
Loire-Atlantique, France). We studied variations in rela-
tive centrifugal force (RCF), temperature, and time for
optimizing conditions for platelet isolation. After the
first centrifugation, the whole plasma above the buffy
coat was collected, separating platelets from red blood
cells and leukocytes (PRP1). For the optimization of the
second centrifugation step, only the RCF and time were
studied. PRP1 from single donors was divided into 1 ml
fractions and after the second centrifugation step the
platelet pellet was suspended in 300 μl of platelet-poor
plasma (PPP; new fraction named PRP2). PRP2 was acti-
vated using 20 mM CaCl2 (PRP2-Ca) or 20 mM CaCl2
plus 25 IU/ml human plasma thrombin (PRP2-Thr, Ref:
T6884; Sigma-Aldrich, St. Louis, Missouri, USA). All
samples were incubated at 37°C for 1 hour and at 4ºC
for 16 hours. For recovering the activated PRP2, all of
the treated samples were centrifuged at 3,000 × g for 20
minutes at 18°C. The supernatant (activated PRP2) was
collected by aspiration. Clots were treated with 200 mM
HCl for 10 minutes and neutralized with 240 mM
NaOH (washed clot). All samples were stored at –80ºC.
Hematological analysis
The total blood cell count was determined in whole blood,
PRP1, PRP2 and PPP fractions. Platelet counts were
performed with a hemocytometer using a Wintrobe-
modified REES-ECKER fluid and other blood cell types
were analyzed using a hematological analyzer XE-2100
(Sysmex, Kobe, Hyōgo, Japan).
Cytokines quantification
Samples from peripheral blood, PRP1, PRP2, PPP, activated
PRP2 and washed clot were analyzed. Proinflammatory cy-
tokines granulocyte–macrophage colony-stimulating factor
(GM-CSF), interleukin (IL)-1β, IL-6, IL-8, tumor necrosis
factor (TNF)α, interferon (IFN)g, IL-2, IL-2R, IL-7, IL-
12p40/p70, IL-15, IL-17), anti-inflammatory cytokines (IL-
1RA, IL-4, IL-5, IL-10, IL-13, IFNα), chemokines (eotaxin,
protein 10 (IP-10), monocyte chemoattractant protein-1(MCP-1), IFNγ-induced monokine, macrophage inflamma-
tory protein (MIP)-1α, MIP-1β, RANTES) and growth fac-
tors (endothelial growth factor (EGF), hepatocyte growth
factor (HGF), basic fibroblast growth factor (bFGF), gran-
ulocyte colony-stimulating factor (G-CSF), vascular endo-
thelial growth factor (VEGF), transforming growth factor
(TGF)-β1, TGF-β2, TGF-β3, platelet-derived growth factor
(PDGF)-AA, PDGF-AB, PDGF-BB, insulin-like growth
factor-1 (IGF-1)) were quantified. Commercial ELISA and
Luminex kits were used: Quantikine hPDGF-AB ELISA
(R&D, Minneapolis, Minnesota, USA), Human Cytokine
30-plex Assay (Invitrogen, Carlsbad, California, USA),
Fluorokine MAP TGF-β Multiplex Kit (R&D, Minneapolis,
Minnesota, USA), Human Angiogenesis Fluorokine Multi
Analyte Profiling Kit (R&D, Minneapolis, Minnesota, USA)
and Milliplex MAP Human IGF-1 Single Plex Kit
(Millipore, Billerica, Massachusetts, USA). Procedures were
carried out following the manufacturer’s instructions.
Statistical analysis
Results are expressed as mean ± standard deviation for at
least three replicates. Statistical significance was assessed by
one-way nonparametric analysis of variance followed by the
Tukey post-hoc test (to compare all pairs in group) or
Dunnett’s multiple comparison test (to compare every con-
dition with control data but not with each other). P <0.05
was considered statistically significant. Statistical analysis
was performed using Prism 5.00 software (GraphPad Soft-
ware Inc., San Diego, California, USA).
Results and discussion
Optimization of the platelet-rich plasma preparation
method
After initial analyses of experimental results, we decided to
optimize blood processing in two centrifugation steps, de-
scribed as follows. The aim of the first step was to deplete
the product of red and white blood cells with minimal loss
of platelets, and the aim of the second step was to obtain
the highest recovery and the best yield of platelets in the
smallest final plasma volume.
First centrifugation step
Freshly collected blood was centrifuged as described in
Materials and methods, yielding three fractions: a lower
dense layer containing red blood cells occupying about
one-half of the total blood volume, a thin intermediate
white layer containing leukocytes (buffy coat) and the
upper yellow fraction containing platelets (PRP1).
The RCF, time and temperature were considered vari-
ables to be optimized, since they could potentially influence
the final platelet yield and purity. These three variables are
highly correlated, so one-at-a-time parameter variation
would not be suitable to find the best condition because,
for example, a temperature increase would reduce plasma
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under the same centrifugation conditions; also longer cen-
trifugation times would better combine with low RCF, so
platelets are still isolated in the upper fraction.
We ran 17 experiments, including 15 different condi-
tions; one condition was repeated three times for error
estimation. The results are presented in Table 1. We ob-
served that increasing the RCF from 200 to 360 × g was
detrimental for both yield and recovery. The same nega-
tive effect was observed when increasing the centrifuga-
tion time. When analyzing temperature influence, no
effect was detected when centrifugation times were
short; but when the centrifugation step took 16 minutes,
temperature had a positive effect and increased the
platelet yield. Based on these analyses, we have chosen
five conditions (runs 5, 8, 11, 13 and 15) that were re-
peated for different blood samples. We confirmed plate-
let yield and recovery, showing reproducibility between
days and among different donors (Figure 1). Platelet re-
covery and yield were statistically lower for condition 2
(360 × g, 16 minutes, 16°C), carried out at the highest
RCF. The best performance was obtained using parame-
ters from condition 3 (300 × g, 5 minutes, 12°C), the one
with the lowest centrifugation time. Since a significant
difference was not observed with condition 1 (240 × g, 8













1 240 8 8 2.5 66.6
2 360 8 8 0.9 30.4
3 240 16 8 1.3 52.7
4 360 16 8 0.5 19.5
5 240 8 16 2.6 69.3
6 360 8 16 1.1 33.2
7 240 16 16 1.6 10.4
8 360 16 16 1.8 73.7
9 200 12 12 2.4 82.7
10 400 12 12 0.6 24.2
11 300 5 12 5.2 87.7
12 300 19 12 0.7 28.2
13 300 12 5 1.6 62.7
14 300 12 19 0.8 30.3
15 300 12 12 1.8 73.6
16 300 12 12 1.3 53.7
17 300 12 12 1.7 69.1
RCF relative centrifugal force.further optimization of the second step, because of its
shorter time.
To monitor the platelet purity in PRP1, we quantified
other cell types and we observed that erythrocytesFigure 1 Platelet yield, recovery and platelet-rich plasma
volume after the first blood centrifugation step. (A) Platelet
yield, (B) recovery and (C) PRP1= platelet-rich plasma after the first
blood centrifugation step. Values expressed as mean ± standard
deviation. Different letters indicate statistically significant differences
(analysis of variance followed by Tukey post-hoc test, n = 3, α = 0.05).
Condition 1: 240 × g, 8 minutes, 16°C; condition 2: 360 × g, 16 minutes,
16°C; condition 3: 300 × g, 5 minutes, 12°C; condition 4: 300 × g,
12 minutes, 5°C; condition 5: 300 × g, 12 minutes, 12°C.
Table 2 Red blood cell and while blood cell quantification in whole blood and PRP1 fractions
Condition Volume (ml) RBC (106/μl) WBC (103/μl)
Whole blood 4.1 ± 1.4 4.05 ± 0.28 (100%) 4.38 ± 0.47 (100%)
1 (240 × g, 8 minutes, 16°C) 1.7 ± 0.2 0.02 ± 0.00 (0.19%) 0.02 ± 0.02 (0.21%)
2 (360 × g, 16 minutes, 16°C) 2.2 ± 0.1 0.00 ± 0.00 (0%) 0.00 ± 0.00 (0.12%)
3 (300 × g, 5 minutes, 12°C) 1.5 ± 0.4 0.03 ± 0.01 (0.24%) 0.03 ± 0.01 (0.28%)
4 (300 × g, 12 minutes, 5°C) 2.0 ± 0.1 0.01 ± 0.00 (0.12%) 0.01 ± 0.00 (0.12%)
5 (300 × g, 12 minutes, 12°C) 2.1 ± 0.2 0.01 ± 0.00 (0.13%) 0.01 ± 0.01 (0.08%)
Values expressed as mean ± standard deviation (remaining amount of contaminant cells in PRP1, related to the initial amount and corrected by the corresponding
volume). RBC red blood cell, WBC white blood cell, PRP1 platelet-rich plasma after the first centrifugation step. n = 3.
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PRP1 and remained at a very low concentration (<0.3%
compared with their initial concentration for both cell
types; Table 2).Second centrifugation step
When optimizing the second centrifugation step, the
temperature was fixed at 12°C since analyses of the first
step indicated that it did not affect significantly platelet
recovery and yield. Table 3 shows the results for the dif-
ferent conditions studied, where partial platelet yield in
the platelet-rich fraction of the second run (PRP2) and
partial platelet recovery in the PRP2 and the PPP were
determined. In some centrifugation conditions, total
platelet recovery (PRP2 plus PPP recovery values) did
not reach 100%, possibly due to platelet aggregation. Im-
portant losses were observed at low RCF and the best










1 200 7 1.8 47.1 51.3 98.4
2 700 7 1.4 39.7 0.0 39.7
3 200 17 2.1 55.9 8.5 64.4
4 700 17 3.6 97.4 0.5 97.9
5 450 12 2.7 75.5 3.6 79.1
6 450 12 2.8 78.1 3.4 81.5
7 450 12 3.2 88.9 5.3 94.2
8 100 12 1.4 38.9 52.0 90.9
9 800 12 3.3 93.2 0.0 93.2
10 450 5 1.8 48.3 20.1 68.4
11 450 19 2.5 65.7 0.0 65.7
PPP platelet-poor plasma, PRP1 platelet-rich plasma after the first blood
centrifugation step, PRP2 platelet-rich plasma after the second centrifugation
step, RCF relative centrifugal force.centrifugation times. Condition 4 (700 × g, 17 minutes),
condition 5 (450 × g, 12 minutes) and condition 9
(800 × g, 12 minutes) where further confirmed using dif-
ferent blood samples (n = 3).
Although the platelet recovery was not statistically
different from the other two conditions (P = 0.3222),
condition 4 (700 × g, 17 minutes) was chosen since it
allowed a lower platelet loss into the PPP fraction
(Figure 2A) and produced a pellet that was easily
resuspended. For all three conditions, erythrocytes and
leukocytes were quantified in both samples, PRP2 and
PPP. PPP was free from erythrocytes and leukocytes. All
of the remaining contaminant cells were centrifuged to-
gether with the platelets; <0.3% of the initial red and
white blood cells remained in PRP2, defining our prepar-
ation as a leukocyte-poor PRP.Temperature effect on platelet-rich plasma preparation
method
Considering that temperature did not affect platelet iso-
lation during the first step, the whole procedure was
tested at 12°C and at 18°C (room temperature). Results
are shown in Table 4 and also in Figure 2. No significant
differences were observed between both temperatures.Method reproducibility
We tested the same procedure for different patients and
on different days. The results are shown in Figure 3. For
some patients (for example, Patients 1, 5 and 7) repro-
ducibility was high, showing almost no difference bet-
ween the two days.Confidence interval
Considering 18 different samples and α = 0.05, our
newly optimized PRP preparation method allowed us
to obtain a final platelet recovery of 46.9 to 69.5%,
yielding a concentration factor between 5.4 and 7.3
and a final platelet concentration of 1.4 × 106 to 1.9 × 106
platelets/μl.
Figure 2 Temperature effect on platelet loss in platelet-poor plasma fraction after the second centrifugation step. First centrifugation
was performed at the corresponding temperature: (A) 12°C and (B) 18°C. *Statistically significant differences (analysis of variance followed by
Tukey post-hoc test, n = 3, α = 0.05). PPP, platelet-poor plasma.
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In conclusion, the present study developed and charac-
terized the following two-step method to obtain PRP,
maximizing platelet purity, recovery and yield:
1) Blood samples were collected in 5 ml tubes
containing 3.2% sodium citrate; a 100 μl sample was
separated for determining the initial blood cell
concentration.
2) Whole blood was centrifuged at 300 × g during 5
minutes at 18°C.
3) The upper fraction (PRP1) was separated, without
disturbing the buffy coat, and was transferred into a
sterile tube; the PRP1 volume was quantified and a
100 μl sample was separated for determining PRP1
platelet concentration and purity.
4) PRP1 was centrifuged at 700 × g during 17 minutes
at 18°C.
5) PPP was transferred into a sterile tube and the
platelet concentration and purity were quantified.
6) The platelet pellet obtained from 1 ml PRP1 was
resuspended in 300 μl PPP (PRP2).
7) Platelet activation was performed immediately by
adding 20 mM CaCl2 and 25 IU/ml humanTable 4 Temperature effect on platelet-rich plasma
preparation method
12°C 18°C P value
PRP1 (300 × g, 5 minutes)
Platelet recovery (%) 90.6 ± 21.7 87.7 ± 22.8 1.0000
Platelet yield (fold) 3.1 ± 0.7 2.9 ± 0.6 0.5066
PRP1 volume (%) 26.7 ± 0.7 27.6 ± 1.9 0.7000
PRP2 (700 × g, 17 minutes)
Platelet recovery (%) 80.3 ± 26.6 86.0 ± 46.9 1.0000
Platelet yield (fold) 9.3 ± 2.6 8.8 ± 3.6 0.8248
Analysis of variance test (n = 3, α = 0.05). PRP1 platelet-rich plasma after the
first blood centrifugation step, PRP2 platelet-rich plasma after the second
centrifugation step.thrombin or CaCl2 alone, incubating at 37°C during
1 hour and at 4ºC during 16 hours.
8) Activated PRP2 was recovered by centrifugation at
3,000 × g during 20 minutes at 18°C.
We decided to collect blood in citrated glass tubes.
Although Araki and colleagues recommended use of
ethylenediamine tetraacetic acid to maximize platelet re-
covery [42], ethylenediamine tetraacetic acid use resulted
in damaged platelets according to Landersberg and col-
leagues [43].
Anitua proposed in 1999 a simple method for ob-
taining PRP that has been frequently used in subsequent
studies and in clinical application [44]. A fraction of 0.5
ml plasma located just above the buffy coat separated
after a single centrifugation cycle (460 × g, 8 minutes)
was collected. The upper fraction was considered PPP,
since the author argued that platelet density was gra-
dually increasing from the top to the buffy coat. In con-
trast, we did not find any platelet gradient in any of
PRP1 fractions (data not shown), and we decided to
recover the whole PRP1volume for the next centrifuga-
tion step.
The second high-speed centrifugation step concen-
trated platelets by one-tenth from the initial blood vol-
ume, leaving a PPP fraction with <1% platelet loss. We
concentrated platelets, reaching a baseline of 1 million
platelets/μl, finally recovering at least 50% of the initial
platelet amount. These parameters are higher than those
reported for commercial PRP kits: Sundman and col-
leagues reported a 1.99-fold increase in platelet con-
centration using an Arthrex ACP kit, minimizing the
leukocyte content (0.13×); the same authors reported a
4.69-fold and 4.26-fold increase in platelet and leukocyte
concentration, respectively, using a Biomet GPS III kit
[45]. Mazzucco and colleagues compared four diffe-
rent PRP protocols: three commercially available kits
(Fibrinet, RegenPRP-Kit and Plateltex) and a homemade
procedure, obtaining a 1.6-fold to 4.4-fold increase in
Figure 3 Individual and daily variation of a platelet-rich plasma preparation at 18°C. (A) PRP2 platelet recovery and (B) PRP2 platelet yield.
Samples belong to different donors and the procedure was performed by different researchers on different days. PRP2, platelet-rich plasma
volume after the second blood centrifugation step.
Amable et al. Stem Cell Research & Therapy 2013, 4:67 Page 7 of 13
http://stemcellres.com/content/4/3/67platelet concentration [29]. Le and colleagues compared
a Curasan PRP kit, Plateltex, GPS II, RegenLab and a
homemade protocol [30]. They obtained a 2.75-fold,
3.43-fold, 1.89-fold, 1.55-fold and 1.77-fold increase in
platelet concentration and platelet recovery of 32.0%,
20.0%, 22.6%, 79.0% and 45.6%, respectively. Castillo and
colleagues compared the Biomet GPS III, MTF Cascade
and Arteriocyte Magellan systems and showed that
platelet recovery was 22.6%, 67.6% and 65.5%, with a
2.07-fold, 1.62-fold and 2.80-fold increase in platelet
concentration, respectively [31]. We obtained a high
platelet recovery and a 6.4-fold increase in platelet con-
centration, making better use of the donor’s blood and
requiring a smaller volume to obtain the same platelet
amount.
Our PRP preparation is highly purified and contains
almost no blood-derived cell types other than platelets.
Leukocytes should be avoided in PRP preparations be-
cause of their potential proinflammatory effect [23,37,45].
Sundman and colleagues recently concluded from in vitro
studies that leukocytes increased the catabolic PRP pro-
file, since the catabolic cytokine concentration (matrix
metalloproteinase-9 and IL-1β) was positively correlated
with leukocyte concentration, but no correlation be-
tween leukocyte content and clinical effects in vivo has
been reported to our knowledge [45].
Growth factor and cytokine content quantification
A total of 37 growth factors and cytokines were quan-
tified in different fractions obtained during PRP pre-
paration: initial blood sample plasma, PRP1, PRP2,
calcium-activated PRP2 (PRP2-Ca), calcium plus human
thrombin-activated PRP2 (PRP2-Thr), PPP, and clot
washing. Only 12 factors and cytokines were secreted
from activated platelets, this being defined by statistical
difference: PDGF-AA, PDGF-AB, PDGF-BB, TGF-β1,
TGF-β2, EGF, IL-4, IL-8, IL-13, IL-17, IFNα and TNFα
(Table 5). TGF-β3 and IFNγ were not detected in any of
the fractions analyzed.Growth factors
Figure 4 shows the concentrations of growth factors se-
creted during platelet activation (PDGF-AA, PDGF-AB,
PDGF-BB, TGF-β1, TGF-β2 and EGF). PDGF-AB and
PDGF-BB showed significantly different amounts not
only in activated PRP2 fractions, but also in washed
clots. TGF-β1 and TGF-β2 showed significantly high
growth factor concentration in PRP2-Ca but not in
PRP2-Thr. The TGF clot content was the highest when
compared with other growth factors. We have no infor-
mation regarding the activation state of these two TGF-
β isoforms because the Luminex kit quantified activated
molecules so a sample processing step was performed
before quantification and therefore the total TGF was
detected.
To compare growth factor secretion with other pub-
lications we calculated the secreted cytokine amount
per platelet, since different described protocols resulted
in different platelet concentrations. Expressed by 106
platelets, PRP2-Ca contained 7.9 ± 5.6 pg PDGF-AA,
37.6 ± 14.9 pg PDGF-AB, 20.1 ± 10.0 pg PDGF-BB,
318.6 ± 118.4 pg TGF-β1, 965.2 ± 389.5 fg TGF-β2 and
438.5 ± 195.3 fg EGF.
According to our criteria, growth factors already
present in plasma are IGF-1, with a concentration of
105.30 ± 48.44 ng/ml (P = 0.9734), and hepatocyte
growth factor, whose level was 61.20 ± 39.71 pg/ml
(P = 0.1455). The plasmatic concentration did not give a
significant difference with PRP2-Ca and PRP2-Thr con-
centrations, but they reached values 2.6-fold and 2.5-fold
higher than the plasmatic level, respectively, and we
consider the values indicative of secretion.
Reports on cytokines in PRP are mainly focused on
the growth factors TGF, PDGF, VEGF, EGF, bFGF, HGF
and IGF-1, and available quantitative data concern
PDGF, TGF and EGF. Mazzocca and colleagues reported
that 1,498.1 to 3,020.7 fg EGF were secreted by 106
platelets, higher than the value we found [46]. Compared
with our results, the same group reported a similar
Table 5 Statistical comparison (q-values) of cytokine
concentration between plasma and activated PRP2
Cytokine PRP2-Ca PRP2-Thr Result
PDGF-AA 6.674 5.931 Platelet-secreted factor
PDGF-AB 9.352 9.556 Platelet-secreted factor
PDGF-BB 8.072 7.886 Platelet-secreted factor
IGF-1 0.038 0.302 Plasmatic factor
TGF-β1 5.912 4.143 Platelet-secreted factor
TGF-β2 5.574 3.850 Platelet-secreted factor
TGF-β3 Not detected
EGF 9.243 8.386 Platelet-secreted factor
IL-5 2.568 2.539 Plasmatic factor
IL-6 0.303 0.388 Plasmatic factor
Eotaxin 5.829 6.169 a
bFGF 0.101 1.173 Plasmatic factor
G-CSF 0.081 0.097 Plasmatic factor
GM-CSF 0.711 0.716 Plasmatic factor
HGF 2.657 2.469 Plasmatic factor
IFNα 4.188 2.514 Platelet-secreted factor
IL-1β 0.480 0.590 Plasmatic factor
IL-2 0.869 0.882 Plasmatic factor
IL-2R 0.604 0.256 Plasmatic factor
IL-4 4.894 4.003 Platelet-secreted factor
IL-7 1.881 1.739 Plasmatic factor
IL-1RA 1.216 0.856 Plasmatic factor
IL-8 10.590 9.597 Platelet-secreted factor
IL-10 1.433 1.357 Plasmatic factor
IL-12 2.079 1.070 Plasmatic factor
IL-13 3.884 3.901 Platelet-secreted factor
IL-15 0.001 0.337 Plasmatic factor
IL-17 3.911 3.902 Platelet-secreted factor
VEGF not detected
IFNγ not detected
IP-10 3.131 3.288 Plasmatic factor
MCP-1 4.247 4.392 a
MIG 1.462 1.136 Plasmatic factor
MIP-1α 0.750 1.046 Plasmatic factor
MIP-1β 3.341 2.442 Plasmatic factor
RANTES 0.463 0.839 Plasmatic factor
TNFα 6.752 4.584 Platelet-secreted factor
Determination of platelet-secreted cytokines using the Tukey post-hoc test.
q-value = 3.68 (k = 3, n = 6, α = 0.05). bFGF basic fibroblast growth factor, EGF
endothelial growth factor, GM-CSF granulocyte–macrophage colony-stimulating
factor, HGF hepatocyte growth factor, IGF-1 insulin-like growth factor-1, IP-10
IFNγ-induced protein 10, MCP-1 monocyte chemoattractant protein-1, MIG
IFNγ-induced monokine, MIP macrophage inflammatory protein, PDGF platelet-
derived growth factor, PRP2 platelet-rich plasma after the second centrifugation
step, PRP2-Ca calcium-activated PRP2, PRP2-Thr, calcium plus human thrombin-
activated PRP2, TGF transforming growth factor, VEGF vascular endothelial
growth factor. aEotaxin and MCP-1 showed statistically significant differences due
to concentration reduction but they cannot be classified as platelet-secreted
factors because their concentration was reduced, probably due to degradation
by other products secreted following degranulation, or because they were
associated with secreted molecules.
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and a slightly lower TGF-β1 secretion (161.7 to 185.4
pg/106 platelets) [46]. Other authors reported similar
values for TGF-β1: 120 pg/106 platelets [47], 240 pg/106
platelets [48] and 55.4 to 126.7 pg/106 platelets [45].
Castilho and colleagues reported values similar to ours
regarding PDGF-AB (21.9 to 44.1 pg/106 platelets) and
PDGF-BB (33.3 to 42.3 pg/106 platelets) [31]. Reported
differences reinforce the necessity of standardization of
methods, in order to make the comparative clinical ana-
lyses feasible.
In our study, VEGF was detected in PRP2-Ca samples
of only two out of six donors (1.93 and 1.06 pg/ml), be-
ing lower than the quantification limit of the used assay
(1 pg/ml) in all of the other samples. According to the
manufacturer, isoforms VEGF-121 and VEGF-165 can be
detected with the assay. This is in contrast to most lit-
erature about VEGF and PRP, in which VEGF is consid-
ered one of the major factors: blood concentrations were
reported to be 155 ± 110 ng/ml by Eppley and colleagues
[49] and 50 ± 10 pg/ml by El-Sharkawy and colleagues
[27] and PRP activation resulted in a 6.2-fold and 4.4-fold
increase in VEGF concentration, respectively.
We activated PRP using calcium chloride only (20 mM),
and calcium chloride plus human thrombin (25 IU/ml).
We found statistically significant differences for PRP2-Ca
but not for PRP2-Thr only for TGF-β1, TGF-β2 and IFNα.
Even when differences were not large between the two
activated fractions, these results suggested a better α-
granule content secretion when platelets were activated
using calcium only.
Anti-inflammatory cytokines
IL-1RA, IL-5 and IL-10 showed no significant difference
between activated PRP2 and plasma concentration (P =
0.6837, 0.1483 and 0.5361, respectively). Judging by the
statistical analysis, IL-4 is an intra-platelet factor; the
concentration in plasma (52.86 ± 1.63 pg/ml) and acti-
vated PRP preparations (55.53 ± 1.01 pg/ml for PRP2-Ca
and 55.04 ± 1.30 pg/ml PRP2-Thr) were similar but the
standard deviation was small, making differences statisti-
cally significant (P = 0.0079). Plasmatic IFNα (98.50 ±
13.79 pg/ml) increased by 22.09% and 13.26% in PRP2-
Ca and PRP2-Thr, respectively (P = 0.0305). IL-13 was
twice as concentrated in both activated PRP2 pre-
parations when compared with plasma concentration
(28.91 ± 31.67 pg/ml), but these differences should be
considered indicative only since they were not significant
(P = 0.0618 and 0.0509 for PRP2-Ca and PRP2-Thr, re-
spectively). IL-4, IL-13 and IFNα concentrations are
shown in Figure 5. When PRP2 was activated only with
calcium chloride we obtained 34.9 ± 23.8 fg/106 platelets
for IFNα, 30.3 ± 28.0 fg/106 platelets for IL-4 and 25.2 ±
30.4 fg/106 platelets for IL-13.
Figure 4 Growth factor concentrations secreted after platelet activation. (A) Platelet-derived growth factor (PDGF)-AA, (B) PDGF-AB,
(C) PDGF-BB, (D) endothelial growth factor (EGF), (E) transforming growth factor (TGF)-β1, and (F) TGF-β2. *Statistically significant differences
from the plasmatic concentration (analysis of variance followed by Dunnett’s multiple comparison test, n = 6, α = 0.05). PPP, platelet-poor plasma;
PRP1, platelet-rich plasma after the first blood centrifugation step; PRP2, platelet-rich plasma after the second centrifugation step; PRP2-Ca,
calcium-activated PRP2; PRP2-Thr, calcium plus human thrombin-activated PRP2.
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IL-17, TNFα and IL-8 were the only proinflammatory
cytokines that showed a significant rise from plasma to
activated PRP2 concentrations (P = 0.0206, 0.0008 and
<0.0001, respectively). IL-1β increased its concentration
3.6 times in PRP1 and 9.5 times in PPP when compared
with the plasmatic concentration (0.17 ± 0.27 pg/ml),
but differences should be considered indicative sincethey were not statistically significant (P = 0.7543). The
same results were obtained for granulocyte–macrophage
colony-stimulating factor (P = 0.8456), with smaller in-
creases (1.5-fold and 2.5-fold increase in PRP1 and PPP,
respectively; plasmatic concentration: 5.48 ± 8.49 pg/
ml). In the case of IL-7, there were no significant differ-
ences between plasmatic (10.60 ± 25.96 pg/ml) and acti-
vated PRP2 concentrations (P = 0.3592). Figure 6 shows
Figure 5 Anti-inflammatory cytokine concentration.
Concentrations of (A) IL-4, (B) IL-13, (C) IFNα. *Statistically significant
differences from the plasmatic concentration (analysis of variance
followed by Dunnett’s multiple comparison test, n = 6, α = 0.05).
PPP, platelet-poor plasma; PRP1, platelet-rich plasma after the first
blood centrifugation step; PRP2, platelet-rich plasma after the
second centrifugation step; PRP2-Ca, calcium-activated PRP2; PRP2-Thr,
calcium plus human thrombin-activated PRP2.
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tors secreted during platelet activation. When calculating
the platelet content considering the amount of cytokine
secreted during calcium activation, we obtained 98.5 ±
10.4 fg/106 platelets for IL-8, 32.6 ± 24.2 fg/106 platelets
for IL-17, and 3.1 ± 2.4 fg/106 platelets for TNFα.
While the content of growth factors was not increased
in the PPP, the anti-inflammatory cytokines IL-4 and
IFNα, but not IL-13, and the proinflammatory cytokines
IL-17 and TNFα, but not IL-8, were increased in PPP,
which is obtained after the second centrifugation. Ma-
nipulation of platelets in vitro, as well as sheer stress in
blood vessel circulation, is known to elicit secretion of
cytoplasmic mediators present in platelets into the
pericellular environment, independently of their de-
granulation. We understand that this is the origin of the
four cytokines in the PPP. Some recent reviews discuss
the existence of different α-granules [50-52]. Blair and
Flaumenhaft reviewed the incorporation of plasmatic
proteins into the cell cytoplasm and afterwards into the
α-granules, meaning that platelet membrane rupture can
release factors accumulated into the cytoplasm that are
also concentrated into the α-granules [50]. Ma and col-
leagues reported that different receptors on platelet sur-
face play a role in regulating angiogenesis, with PAR1-
mediated activation allowing platelet aggregation and
VEGF secretion while suppressing endostatin release,
and with PAR4-mediated activation also allowing platelet
aggregation but suppressing VEGF release and stimu-
lating endostatin secretion [53]. White and Rompietti
suggested that this theory of factor segregation into dif-
ferent kinds of granules makes more sense than the
simultaneous secretion of pro-angiogenic and anti-
angiogenic factors that would cause the neutralization of
the effects of the secreted proteins [52].Chemokines
None of the analyzed chemokines was found to have in-
creased content during platelet activation at a statisti-
cally significant level, but MIP-1β showed an increase
from the plasmatic concentration (38.01 ± 34.23 pg/ml)
when compared with PRP2-Ca (118.39 ± 82.39 pg/ml)
and PRP2-Thr (96.76 ± 49.60 pg/ml) – we consider
Figure 6 Proinflammatory cytokine concentration.
Concentrations of (A) IL-8, (B) IL-17, and (C) TNFα. *Statistically
significant differences from the plasmatic concentration (analysis of
variance followed by Dunnett’s multiple comparison test, n = 6,
α = 0.05). PPP, platelet-poor plasma; PRP1, platelet-rich plasma after
the first blood centrifugation step; PRP2, platelet-rich plasma after
the second centrifugation step; PRP2-Ca, calcium-activated PRP2;
PRP2-Thr, calcium plus human thrombin-activated PRP2.
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therefore be further studied. Eotaxin and MCP-1 showed
significantly reduced concentration in activated PRP
fractions; the eotaxin concentration dropped from a plas-
matic concentration of 50.62 ± 16.95 pg/ml to 23.75 ±
8.52 pg/ml in PRP2-Ca and 22.19 ± 4.76 pg/ml in
PRP2-Thr, and the MCP-1 concentration from 245.59 ±
187.52 pg/ml to 69.41 ± 43.27 pg/ml in PRP2-Ca and
78.97 ± 22.20 pg/ml in PRP2-Thr. The reduction may be
caused by degradation of chemokines by the products se-
creted following degranulation, or their association with
secreted molecules, and these issues should also be further
studied.
For chemokines, only one publication for RANTES
was found, reporting a plasmatic concentration of 100 ±
20 ng/mL and activated PRP concentration of 300 ± 100
ng/mL [27]. Our research resulted in plasmatic RANTES
concentrations of 2.76 ± 1.97 ng/mL.
Judging by the PRP composition described here, our
findings support the use of PRP in wound healing and
tissue regeneration, as high concentrations of PDGF and
TGF are secreted from platelet α-granules after acti-
vation. We also showed that growth factors are highly
retained inside clots so, as already demonstrated by
other authors, they would be slowly released in vivo
[54,55]. These growth factors were also described as
mitogenic and attractant for mesenchymal stem cells,
which may continue secreting growth factors and may
mediate regenerative effects during longer periods of
time [56]. Our PRP preparation should now be tested
in vitro in cell cultures in order to reveal its molecu-
lar effects on different cell types and in clinical trials
in order to evaluate its in vivo effects in different
pathologies.Conclusions
Our study optimized a procedure for preparing PRP from
human blood, recovering more than 50% of the initial
platelets with a low amount of other blood cells. This
preparation was activated and different fractions collected
along the procedure were analyzed in order to determine
the growth factor content. Out of 37 proteins quanti-
fied, 12 were shown to be increased only after platelet
activation.
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